Table 3 Baseline characteristics of participants in the CAMPS trial

Age (years) : mean (SD) ^α

40.1 (10.10)

 21-49

157 (79.3)

 50+

41 (20.7)

Gender: n (%)

 Female

147 (73.5)

Level of education: n (%)

 None or primary

78 (39.0)

 Secondary or university

122 (61.0)

Family aware of HIV status: n (%)

180 (90.0)

Presence of an opportunistic infection: n(%)

62 (31.0)

BMI : mean (SD) ^β

25.2 (4.00)

 Underweight

4 (2.2)

 Normal

90 (48.6)

 Overweight

91 (49.2)

CDC* classification - AIDS defining illness§:n (%)

146 (73.0)

Regimen: n (%) ^δ

 First line

179 (90.9)

 Second line

18 (9.1)

Duration on ART (months): median (Q1, Q3) ^α

28.5 (9.0, 48.0)

CD4 (cells per mm ³ ): median (Q1, Q3)

336.0 (200.5,487.7)

Adherence

 Visual Analogue Scale: mean (SD)^ε

90.5 (12.76)

 Number of missed doses: mean (SD)^μ

1.0 (0.00)

 No missed doses: n (%)

127 (65.1)

 Treatment taken on time: n (%)

108 (54.0)

Reasons for missing doses: n (%)

 Forgot

54 (27.0)

 Out of home

23 (11.5)

 Out of tablets

7 (3.5)

 Too busy

8 (4.0)

 Side effects

2 (1.0)

 Other reason

5 (2.5)

Medication side effects experienced: n (%)

 None

127 (63.5)

 One

43 (21.5)

 Two

30 (15.0)

Reminder methods: n (%) ^¥

 None

49 (25.7)

 One

125 (65.4)

 Multiple

17 (8.5)